Tenaya Therapeutics (TNYA) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing curative therapies for heart disease, targeting both rare and prevalent forms using gene therapies and small molecules.

• Lead programs include TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, both in early clinical trials.

• Pipeline includes additional early-stage programs leveraging gene addition, gene editing, gene silencing, and cellular regeneration.

• Proprietary capabilities in target identification, validation, and AAV-based gene therapy manufacturing, with in-house cGMP production for clinical materials.

Financial performance and metrics

• No products approved for sale and no revenue generated to date; company has incurred significant net losses since inception and expects continued losses for the foreseeable future.

• As of December 31, 2024, 86,542,340 shares of common stock were outstanding, with additional shares reserved for options, warrants, and equity plans.

Use of proceeds and capital allocation

• Net proceeds from the offering, together with existing cash, will fund ongoing and planned development of clinical and early-stage product candidates, especially TN-201 and TN-401, as well as working capital and general corporate purposes.

• Proceeds may also be used for in-licensing, acquisitions, or investments in additional businesses, technologies, or assets.

• Management will retain broad discretion over the use of proceeds; current funds are not sufficient to fund clinical programs into late-stage development, necessitating future capital raises.